Update, October 1, 2026: the meeting has happened. PCAC recommended 6 of the 7 peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon) and declined DSIP. See the full vote results and the legal status tracker. The preview below is kept for context.

TL;DR

On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets to discuss whether seven peptides — BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, and DSIP (Emideltide) — should be added to the 503A Bulks List, the list that makes a substance clearly eligible for pharmacy compounding. It’s a real, scheduled meeting, not a rumor. But a PCAC recommendation is advice, not law — and FDA’s own briefing materials ahead of the meeting reportedly lean against adding all seven. Nothing changes for patients on July 23 itself; what changes is the strength of the case for a formal compounding pathway going forward.

The distinction almost everyone gets wrong

People keep treating “off the restricted list” and “cleared for compounding” as the same thing. They aren’t — three separate gates exist:

1. Category 2 (restricted) — a list of substances FDA says compounders should not use due to safety concerns. BPC-157 was added here in September 2023.
2. Off Category 2, but not on Category 1 — the gray zone. BPC-157 left Category 2 in April 2026, but FDA did not move it to the permitted list. It’s simply no longer flagged as restricted; that’s not the same as being approved for compounding.
3. The 503A Bulks List (Category 1) — the actual “yes, pharmacies may compound this” list. Getting onto it requires FDA to evaluate the substance’s chemistry, safety data, and evidence of effectiveness — which is exactly what the July 23–24 PCAC meeting is about.

None of this is the same as FDA drug approval. Even a favorable 503A listing would only mean a compounding pharmacy can legally prepare the substance under a prescription — not that it’s an approved medicine with established efficacy for any condition.

The dated timeline

• Sept 2023 — BPC-157 added to the FDA’s Category 2 (restricted) bulk drug substances list.
• Feb 27, 2026 — HHS signals a policy direction toward loosening peptide restrictions (not a rule change).
• Apr 15, 2026 — FDA formally updates its 503A list; 12 peptides removed from Category 2.
• Apr 23, 2026 — BPC-157 comes off Category 2 specifically.
• Jul 23, 2026 — PCAC discusses BPC-157, KPV, TB-500, and MOTS-c bulk drug substances.
• Jul 24, 2026 — PCAC discusses Emideltide (DSIP), Semax, and Epitalon.

According to FDA’s pre-meeting briefing documents, as reported by trade press covering the docket, the agency’s own analysis leans toward not recommending any of the seven for the 503A Bulks List — citing substances that aren’t well-characterized, thin or absent human evidence of effectiveness, and unresolved safety questions (including adverse-event reports tied to BPC-157, uncertain carcinogenicity signals tied to epitalon’s telomerase activity, and WADA-prohibited status for MOTS-c and TB-500 in competitive sport). That’s FDA staff’s proposed position going into the meeting — not a vote and not a final decision. PCAC’s actual discussion and any recommendation happen on the meeting dates above; FDA then decides separately, on its own timeline, whether to follow it.

What it means for you

• Nothing is banned or approved as of this article’s publish date. The regulatory status of all seven substances is unchanged until FDA acts after the meeting.
• A “yes” from PCAC wouldn’t create over-the-counter access. Even a favorable 503A listing still requires a prescription from a licensed provider and a compliant compounding pharmacy.
• A “no” makes the legitimate compounding pathway narrower, which is exactly why sourcing from unregulated “research chemical” sellers is riskier than ever — those products are unregulated regardless of what PCAC decides.
• Check the current status before acting. Our legal status tracker reflects each peptide’s status today and will update once FDA responds to the PCAC discussion.

If you’re considering any of these peptides, the honest next step is the same regardless of how the meeting goes: talk to a licensed provider who can explain what’s currently legal to prescribe and compound in your state.

Sources

• FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
• Federal Register — PCAC meeting notice
• Drug Topics — “FDA Panel to Evaluate 7 Popular Peptides for Compounding Substances List”
• The FDA Law Blog — “FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know”

← All articles